Clinical Trials Directory

Trials / Completed

CompletedNCT03711331

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia

Impact of a Strategy Based on the Unyvero® Testing System on Appropriate and Targeted Antimicrobial Treatment in Patients With Suspected VAP or HAP Requiring Mechanical Ventilation: a Randomized Controlled Unblinded Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
161 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

VAPERO is a randomized, unblinded, controlled study to measure the impact of a strategy based on the Unyvero® multiplex PCR test on the adjustment of antimicrobial therapy in patients suspected with ventilator-associated or hospital-acquired pneumonia (VAP/HAP) requiring mechanical ventilation. The gold-standard microbiological diagnostic method for pneumonia in the ICU is still culture-based identification and antimicrobial susceptibility testing (AST) despite being more than a hundred years old, with results turnaround time spanning over several days, exposing patients to potentially inappropriate broad-spectrum antimicrobial therapy. The investigators aim to measure the impact of the Unyvero® testing strategy to improve the percentage of patients with VAP or HAP receiving early targeted antimicrobial therapy compared to standard care.

Conditions

Interventions

TypeNameDescription
OTHERFilmArray® Pneumonia panel plusEarly adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
OTHERStandard careStandard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results

Timeline

Start date
2020-06-16
Primary completion
2023-09-22
Completion
2023-09-22
First posted
2018-10-18
Last updated
2026-04-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03711331. Inclusion in this directory is not an endorsement.